Roche raised its earnings guidance for the year after the Swiss drugs group posted better-than-expected results for the first half, with growth in its core businesses helped by new product launches.
Roche raised its earnings guidance for the year after the Swiss drugs group posted better-than-expected results for the first half, with growth in its core businesses helped by new product launches.